Mowerman S, Siris S G
Hillside Hospital Division of the Long Island Jewish Medical Center, Long Island Campus for the Albert Einstein College of Medicine, New York, New York 11004, USA.
Ann Clin Psychiatry. 1996 Dec;8(4):193-7. doi: 10.3109/10401239609147759.
The purpose of this trial was to assess the potential utility of adjunctive treatment with a typical neuroleptic for patients with refractory psychosis insufficiently responsive to clozapine alone. Seven chronic schizophrenic or schizoaffective patients who remained stabilized for at least 9 months on clozapine received open clinical trials with adjunctive loxapine lasting from 18 to 50 weeks. Their symptoms were documented with periodic Brief Psychiatric Rating Scale assessments. All patients improved at least somewhat and two improved remarkably. In the four cases in which the assessment was made, the loxapine had no apparent effect on plasma clozapine levels. We conclude that adjunctive treatment with typical neuroleptics for patients with an incomplete response to clozapine merits further investigation.
本试验的目的是评估对于单独使用氯氮平反应不足的难治性精神病患者，使用一种典型抗精神病药物进行辅助治疗的潜在效用。七名慢性精神分裂症或分裂情感性障碍患者在氯氮平治疗下保持稳定至少9个月，接受了为期18至50周的洛沙平辅助开放临床试验。通过定期的简明精神病评定量表评估记录他们的症状。所有患者至少有一定程度的改善，两名患者改善显著。在进行评估的四例患者中，洛沙平对血浆氯氮平水平无明显影响。我们得出结论，对于对氯氮平反应不完全的患者，使用典型抗精神病药物进行辅助治疗值得进一步研究。
